Format

Send to:

Choose Destination
See comment in PubMed Commons below
Front Pharmacol. 2011 Jun 9;2:28. doi: 10.3389/fphar.2011.00028. eCollection 2011.

Alpha 2 Delta (α(2)δ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome.

Author information

  • 1Clinical Research, Pfizer Global Research and Development Sandwich, UK.

Abstract

Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain and altered bowel habit, and often associates with other gastrointestinal symptoms such as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also frequently coexists with conditions that may also involve central sensitization processes, such as fibromyalgia, irritable bladder disorder, and chronic cough. This review examines the evidence to date on gabapentin and pregabalin which may support further and continued research and development of the α(2)δ ligands in disorders characterized by visceral hypersensitivity, such as IBS. The distribution of the α(2)δ subunit of the voltage-gated calcium channel, possible mechanisms of action, pre-clinical data which supports an effect on motor-sensory mechanisms and clinical evidence that points to potential benefits in patients with IBS will be discussed.

KEYWORDS:

central sensitization; gabapentin; irritable bowel syndrome; motility; peripheral sensitization; pregabalin; visceral sensitivity; α2δdelta ligands

PMID:
21713059
[PubMed]
PMCID:
PMC3114047
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Write to the Help Desk